晚期非小细胞肺瘤的双途径化疗

目的研究不同的化疗方法治疗晚期非小细胞肺癌（NSCLC）并观察其疗效和毒副反应。方法将55例晚期NSCLC患者分4组，A组经皮肺穿刺瘤体内注射卡铂（PCI）+支气管动脉灌注（BAI）双途径化疗13例，B组PCI+VP-16静滴12例，C组单纯BAI18例，D组传统静脉化疗12例进行临床对比观察。结果近期有效率A组为76.9%，B组为58%高于C组33.3%，明显高于D组的16.7%（P<0.01）。一年生存率A组69.2%，B组75%，优于C组的38.9%，更明显优于D组8.3%（P<0.01）。一般状况的改善A、B、C三组明显优于D组（P<0.01）；而毒副反应均明显低于D组（P<0.01）。结论PCI是一种安全、简便的直接介入疗法，联合BAI或VP-16静滴双途径化疗是晚期NSCLC较为理想有效的综合性治疗手段，且PCI+VP-16疗法较PCI+BAI疗法更安全、简便、费用少，并发症少。

Double-pathway chemotherapy for advanced non-small-cell lung cancer

Purpose:To investigate the various methods of chemotherapy in the treatment of advanced non-small-cell lung cancer (NSCLC) Methods:55 patients were allocated to 4 group:the A groups (13 patients were given the ultrasound guided percutaneous intratumor carboplatin injection(PCI) combined with bronchial artery infusion(BAI), the B group (12 patients were given PCI VP-16intravenounaly ),the C group (18 patients) received only BAI and the D group (12 patients) received traditional systemic chemotherapy. The clinical response and the toxic-side reactions were observed.Results:The immediate effective rates were 76.9% in group A, 58% in group B,33% in group C and 16.7% in group D respectively ( P <0.01). The 1-year survival rate was 69.2% in group A , 75% in group B , 38.9% in group C ,8.3% in group D respectively( P <0.01).Conclusions:PCI is a safe and convenient direct interventional therapy .The combined PCI and BAI or intravenous infusion of VP-16 (double pathway chemotherapy) is the ideal,effective therapy for advanced NSCLC ,and the PCI VP-16 combination is a safer, more convenient and cheaper protocol than PCI BAI therapy.